Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables broadly unchanged from a year ago
Net receivables stood at $62.54M at the end of Q1 FY2026, up 1.6% from a year earlier and up 33.0% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.
Context
- Net receivables amounted to 17.3% of total assets at the end of Q1 FY2026, down 2.6 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +1.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 47.03M USD
- Year-over-year change
- +36.8%
- 4-year CAGR
- -2.3%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.03M | +36.8% |
| FY2024 | 2024-12-31 | 34.37M | -12.5% |
| FY2023 | 2023-12-31 | 39.29M | -2.5% |
| FY2022 | 2022-12-31 | 40.28M | -21.9% |
| FY2021 | 2021-12-31 | 51.58M | — |
Net Receivables vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's Mar 2026 net receivables of $62.54M is the highest of the 10 companies compared; the peer median is $3.35M.
- Its year-over-year change of +1.6% is the lowest of 6, against a peer median of +74.5%.
- Net receivables amounts to 17.3% of total assets for AKBA, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $62.54M | +1.6% | +5.3% | 17.3% | |
| Mar 2026 | $49.95M | +20.2% | +8.7% | 9.9% | |
| Mar 2026 | $22.1M | +75.1% | +41.0% | 7.9% | |
| Dec 2025 | $11.3M | — | — | 3.4% | |
| Mar 2026 | $9.35M | +42.1% | — | 7.3% | |
| Mar 2026 | $3.35M | +74.5% | +133.4% | 0.6% | |
| Mar 2026 | $1.2M | +427.8% | -16.1% | 0.5% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AKBA) | $3.35M | +74.5% | +24.8% | 0.6% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 149.8M | 90.47M | 42.93M | 51.87M | 184.84M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 51.58M | 40.28M | 39.29M | 34.37M | 47.03M |
| Inventory | 36.63M | 21.57M | 15.69M | 16.24M | 15.61M |
| Other Current Assets | 0 | 32.86M | 20.24M | 7.32M | (62.64M) |
| Total Current Assets | 271.15M | 185.18M | 118.15M | 113.83M | 184.84M |
| Property, Plant & Equipment (Net) | 40.61M | 34.37M | 16.05M | 10.42M | 0 |
| Goodwill | 59.04M | 59.04M | 59.04M | 59.04M | 59.04M |
| Intangible Assets | 108.13M | 72.08M | 36.04M | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 50.42M | 5.37M | 12.42M | 37.38M | 132.68M |
| Total Non-current Assets | 258.2M | 170.87M | 123.55M | 106.84M | 191.72M |
| Total Assets | 529.35M | 356.05M | 241.7M | 220.67M | 376.57M |
| Account Payables | 33.59M | 18.02M | 14.64M | 15.18M | 21.19M |
| Short-term Debt | 97.54M | 32M | 19.55M | 4.31M | 40.08M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 20.91M | 3.74M | 0 | 0 | 0 |
| Other Current Liabilities | 31.18M | 52.53M | 18.26M | 22.75M | 101.67M |
| Total Current Liabilities | 261.05M | 129.54M | 99.87M | 80.91M | 162.94M |
| Long-term Debt | 53.08M | 34.08M | 71.2M | 175.47M | 176.21M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 21.47M | 43.3M | 43.3M | 0 | 0 |
| Other Non-current Liabilities | 86.03M | 114.95M | 48.98M | 9.93M | 4.8M |
| Total Non-current Liabilities | 194.29M | 221.29M | 172.42M | 188.94M | 181.02M |
| Total Liabilities | 455.34M | 350.82M | 272.29M | 269.86M | 343.96M |
| Common Stock | 1K | 2K | 2K | 2K | 2K |
| Retained Earnings | (1.46B) | (1.56B) | (1.61B) | (1.68B) | (1.68B) |
| Accumulated OCI | 6K | 6K | 6K | 6K | 6K |
| Other Stockholders Equity | 0 | 0 | 0 | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 74.01M | 5.23M | (30.58M) | (49.19M) | 32.61M |
| Total Debt | 189.13M | 99.78M | 104.18M | 188.73M | 216.3M |
| Net Debt | 39.33M | 9.32M | 61.26M | 136.86M | 31.45M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.